ACLX Overview
Upcoming Projects (ACLX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ACLX)
-
A Second Opinion: Looking at the new results from the Phase 3 CARTITUDE-4 study of CARVYKTI presented at ASH2024, as well as the Phase II iMMagin data on Anito-Cel from Gilead/Arcellx
Tickers: JNJ, GILD, ACLX
Executed On: Jan 03, 2025 at 12:00 PM EST -
Looking at the new results from the Phase 3 CARTITUDE-4 study of CARVYKTI presented at ASH2024, as well as the Phase II iMMagin data on Anito-Cel from Gilead/Arcellx
Tickers: JNJ, GILD, ACLX
Executed On: Dec 31, 2024 at 12:00 PM EST -
A Second Look: Discussing the new data available from ASH 2023 with a focus on Arcellx’s Phase 1 Study of Anito-cel in patients with relapsed or refractory multiple myeloma
Ticker: ACLX
Executed On: Dec 15, 2023 at 05:00 PM EST -
Discussing the new data available from ASH 2023 with a focus on Arcellx’s Phase 1 Study of Anito-cel in patients with relapsed or refractory multiple myeloma
Ticker: ACLX
Executed On: Dec 14, 2023 at 04:00 PM EST -
Examining the multiple myeloma treatment landscape and the potential use of CART-ddBCMA currently in phase 1 trial by Gilead Science and Arcellx presented at the ASH Conference
Tickers: GILD, ACLX
Executed On: Feb 14, 2023 at 01:00 PM EST -
A look at the potential of new CAR-T cell therapies in development for multiple myeloma
Tickers: ACLX, GRCL, OriCell Therapeutics, JNJ, LEGN, TSVT
Executed On: Jul 14, 2022 at 08:00 AM EDT
Upcoming & Overdue Catalysts (ACLX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ACLX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
